Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. 2020 ESC Guidelines for the management of adult congenital heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognosis of myocardial infarction-related cardiogenic shock according to preadmission out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Short-term prognosis of normalising serum potassium following an episode of hypokalaemia in patients with chronic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: The study aimed to estimate the risk of cardiac events in immune checkpoint inhibitor (ICI)-treated patients with lung cancer or malignant melanoma.

METHODS AND RESULTS: The study included consecutive patients with lung cancer or malignant melanoma in 2011-17 nationwide in Denmark. The main composite outcome was cardiac events (arrhythmia, peri- or myocarditis, heart failure) or cardiovascular death. Absolute risks were estimated and the association of ICI and cardiac events was analysed in multivariable Cox models. We included 25 573 patients with lung cancer. Of these, 743 were treated with programmed cell death-1 inhibitor (PD1i) and their 1-year absolute risk of cardiac events was 9.7% [95% confidence interval (CI) 6.8-12.5]. Of the 13 568 patients with malignant melanoma, 145 had PD1i and 212 had cytotoxic T-lymphocyte-associated protein-4 inhibitor (CTLA-4i) treatment. Their 1-year risks were 6.6% (1.8-11.3) and 7.5% (3.7-11.3). The hazard rates of cardiac events were higher in patients with vs. without ICI treatment. Within 6 months from 1st ICI administration, the hazard ratios were 2.14 (95% CI 1.50-3.05) in patients with lung cancer and 4.30 (1.38-13.42) and 4.93 (2.45-9.94) in patients with malignant melanoma with PD1i and CTLA-4i, respectively. After 6 months, HRs were 2.26 (1.27-4.02) for patients with lung cancer and 3.48 (1.91-6.35) for patients with malignant melanoma and CTLA-4i.

CONCLUSIONS: Among patients with lung cancer and malignant melanoma, ICI treated had increased rates of cardiac events. The absolute risks were higher in these data compared with previous pharmacovigilance studies (e.g. 1.8% peri-/myocarditis 1-year risk).

OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
ISSN0195-668X
DOI
StatusUdgivet - 9 dec. 2020

Bibliografisk note

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

ID: 61434338